Share

August 19, 2014; 83 (8) Article

Clinical-pathologic study of depressive symptoms and cognitive decline in old age

Robert S. Wilson, Ana W. Capuano, Patricia A. Boyle, George M. Hoganson, Loren P. Hizel, Raj C. Shah, Sukriti Nag, Julie A. Schneider, Steven E. Arnold, David A. Bennett
First published July 30, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000715
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
924

Share

Article Information

vol. 83 no. 8 702-709
DOI: 
https://doi.org/10.1212/WNL.0000000000000715
PubMed: 
25080520
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received February 6, 2014
  • Accepted in final form May 17, 2014
  • First Published July 30, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Robert S. Wilson, PhD,
    2. Ana W. Capuano, PhD,
    3. Patricia A. Boyle, PhD,
    4. George M. Hoganson, MD,
    5. Loren P. Hizel, BA,
    6. Raj C. Shah, MD,
    7. Sukriti Nag, MD,
    8. Julie A. Schneider, MD,
    9. Steven E. Arnold, MD and
    10. David A. Bennett, MD
  1. Robert S. Wilson, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Aging, Neuropsychology, and Cognition, Consulting Editor, 2004-present; (2) Psychology and Aging, Consulting Editor, 2007-present; (3) Neuropsychology, Consulting Editor, 2014-present.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Pain Therapeutics, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIA R01AG17917, Co-I, 2001-2014; (2) NIH/NIA P30AG10161, Co-I, 1991-2014; (3) NIH/NIA R01AG34374, Co-I, 2008-2014; (4) NIH/NIA R01AG15819, Co-I, 1998-2014.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ana W. Capuano, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH (R01AG022018 [co-investigator], R01AG017917 [co-investigator], R01AG015819 [co-investigator], P30AG010161 [co-investigator], R01AG043379 [co-investigator], R01HL096944 [co-investigator], and R01AG040039 [co-investigator]).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Patricia A. Boyle, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIA R01AG034374, PI; (2) NIH/NIA R01AG033678, PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. George M. Hoganson, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Loren P. Hizel, BA,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIA, R01AG017917 & P30AG10161, research assistant, 2010-2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Raj C. Shah, MD,
    7. Scientific Advisory Boards:

    1. advisory board service for (1) Merck & Co., Inc. (2) Genentech, Inc.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Journal of Alzheimer's Disease, Associate Editor, 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Danone Trading B.V. (2) W. Health, L.P.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Danone Research B.V. (2) Eli Lilly & Co., Inc. (3) Genentech, Inc. (4) Merck & Co., Inc. (5) Metabolic Solutions Development Company (6) Navidea Biopharmaceuticals (7) Takeda Development Center Americas, Inc.

    Research Support, Government Entities:

    1. (1) NIH, P30 AG101061, Education and Information Transfer Core Leader and Clinical Core Coinvestigator, 2009-present (2) NIH, P20 MD006886, Leader, Education/Research Training Core & Co-investigator, Community Engagement/Outreach Core, 2012-present (3) NIH U01 AG010483, Site Investigator, 2004-present (4) NIH U01 AG029824, Site Principal Investigator, 2009-present (5) NIH, U01 AG046152, Coinvestigator, 2013-present (6) NIH U01, AG024904, Site Coinvestigator, 2004-2013, Site Principal Investigator 2013-present (7) NIH, RC2 AG03653501, Site Investigator, 2009-2012 (8) NIH R01 AG011101, Examining Geriatrician, 2002-2012 (9) NIH R01 NR009543, Coinvestigator, 2007-2013 (10) NIH, P01 AG009466, Coinvestigator, Administrative Core, 2004-2013 (11) Illinois Department of Public Health, Alzheimer�s Disease Assistance Center, Associate Director, 2012-present (12) PCORI, CDRN-1306-04737, Site Principal Investigator, 2014-present (13) Center for Medicare & Medicaid Services, FP050658, Site Principal Investigator, 2012-present (14) DOD, W81XWH-12-2-0012, Site Investigator, 2012-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Sukriti Nag, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. The blood-brain & Other neural barriers, Springer Science + Business Media,Humana Press, 2011 Nag S (Editor)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Julie A. Schneider, MD,
    9. Scientific Advisory Boards:

    1. 1. served on scientific advisory board for GE Healthcare (2010) 2. served on scientific advisory board for Eli Lilly and Company (2011) 3. served on advisory board for Genetech (2013)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 2005-current Journal Histochemistry and Cytochemistry (Monitoring editor) 2008-current International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) (Editorial Board) 2010 Journal of Alzheimer's Disease (Associate Editor)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Neuropathology consultant, AVID radiopharmaceuticals 2009-12

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. AVID radiopharmaceutical phase III clinical trial Neuropathologist 2010-2011

    Research Support, Government Entities:

    1. 1R01AG042210 (Schneider) 07/1/12- 06/30/17 Epidemiologic Study of TDP-43 Pathology in Aging and Dementia Major goal is to determine whether age-related TDP-43 pathology represents a separate pathologic process associated with a dementia syndrome with a distinct cognitive phenotype and specific genetic risk factors that are separate from AD. Role: Principal investigator R01NS078009 (Buchman) 9/15/12-6/30/17 NINDS The Clinical Profile of Parkinson's Disease (PD) Pathology. The overall goal is to characterize the clinical profile of PD pathology in older persons without a diagnosis of PD. Role: co-investigator R01AG043379 (Buchman) 9/30/12-8/31/17 NIA Brain and Spinal Cord Microvascular Pathology in Late-Life Motor Impairment The overall goal is to test the hypothesis that specific microvascular pathologies in the brain and spinal cord contribute to late-life motor impairment. U01AG016976 (Kukull/Montine) 7/1/12-6/30/13 NIA (Pilot) Optimization of Neuropathologic Assessment of Alzheimer�s Disease; The overall goal is to optimize neuropathologic diagnosis of Alzheimer�s disease for uniformity and accurancy across centers Role: Site Principal Investigator P30 AG10161 (Bennett) 9/30/91-6/30/16 Rush Alzheimer's Disease Core Center Major goals to provide core infrastructure support for research regarding aging/dementia/AD. Role: Associate Director, Core Leader: Neuropathology Core R01 AG031553 (Morris) 3/15/08 � 2/28/13 Epidemiologic Study of Brain Vitamin E, Diet, and Age-Related Neurologic Diseases; Major goal is analyze Vitamin E in brain, CSF, serum, and diet and compare to neuropathology and dementia. Role: Co-Principal Investigator R01 AG17917 (Bennett) 9/30/01-6/30/13 Epidemiologic Study of Neural Reserve and Neurobiology of Aging; Major goals are to identify structural bases of reserve and examine mechanisms risk factors lead to age-related functional impairment. Role: Co-Investigator R01 AG15819 (7/1/98 � 6/30/13 Risk Factors, Pathology and Clinical Expressions of AD The major goals of this project are to examine the pathologic mechanisms through which risk factors lead to clinical AD. Role: Co-investigator P01 AG14449 (Mufson) 9/1/97 � 3/31/13 Neurobiology of Mild cognitive impairment in the Elderly; The major goals are to identify neurobiologic substrates of mild cognitive impairment. Role: Co-investigator (Neuropathologist) R01AG033678-01 (Boyle) 9/15/2009 - 6/30/14 Epidemiologic study of impaired decision making in preclinical Alzheimer�s disease. The overall goal of the proposed epidemiologic study is to examine the causes and consequences of impaired decision-making in old age. Role: Neuropathologist R01AG034374 (Boyle) 8/15/2009 -7/31/14 Characterizing the behavior profile of healthy cognitive aging. Goal is to use innovative statistical approaches to characterize the profile of healthy cognitive aging defined as age-related cognitive change not accounted for by the presence of common neuropathologies (i.e., Alzheimer's disease, cerebral infarcts, and the Lewy body diseases) or terminal decline. Role: Neuropathologist. P01 AG09466 (deToledo-Morrell) 4/1/1991-8/31/12 Anatomic, Physiologic, Cognitive Pathology of AD; major goals- to identify neurobiologic, radiologic, physiologic, cognitive markers with AD; Role: Co-Investigator; Neuropathologist, Administrative Core R01 AG36042 (Bennett) 9/15/09-8/31/14 Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experiences The goal of the study is to examine the relation of DNA methylation to cognitive decline and life experiences. Role: Neuropathologist R01 HL096944 (Levine) 9/1/09 � 6/30/13 Stroke and aPL: Community-Based Clinicopathologic Study The major goal of this project is to investigate the role and mechanisms of antiphospholipid antibodies (aPL) in the development of pathologically-proven ischemic brain infarction. Role: Neuropathologist R01AG040039 (Arvanitakis) 9/30/11-8/31/16 National Institute on Aging Vascular Cognitive and Motor Decline: Impact of aPL The major goal of this project is to investigate the role and mechanisms of antiphospholipid antibodies (aPL) in the development of cognitive and motor decline in aging. R01AG039478 (Arnold) 4/1/11-3/31/16 National Institute on Aging Targeted Proteomics of Resilient Cognition in Aging The major goal of the study is to identify candidate proteins and pathways that best confer cognitive resilience despite the accumulation of neurodegenerative disease pathology. Role: Neuropathologist R01AG036836 (DeJager) 9/15/11-8/31/15 National Institute on Aging Exploring the Role of the Brain Transcriptome in Cognitive Decline The major goal is to investigate the transcriptome of human brain tissue to identify molecular pathways that contribute to cognitive decline. Role: Neuropathologist

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Steven E. Arnold, MD and
    10. Scientific Advisory Boards:

    1. Teva

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Eli Lilly; Pfizer; Merck; Neuronetrix; Johnson & Johnson; Baxter; Tohyama

    Research Support, Government Entities:

    1. NIH

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Marian S. Ware Family Foundation Barra Foundation; BrightFocus Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. David A. Bennett, MD
    11. Scientific Advisory Boards:

    1. (1) Vigorous Minds, Scientific Advisory Board (2) Takeda Pharm - Adjudication committee AD4833/TOMM40_301 study

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Nutricia, paid for travel to scientific meeting

    Editorial Boards:

    1. (1) Neurology, Editorial Board; (2) Current Alzheimer Research, Editorial Board; (3) Neuroepidemiology, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Nutricia, Inc., (2) Eli Lilly, Inc., (3) Enzymotec Ltd.,

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Nutricia Inc., co-PI (2) Zinfandel, PI

    Research Support, Government Entities:

    1. NIH: P30AG10161, PI; R01AG15819, PI; R01AG17917, PI; R01AG36042, PI; U01AG32984, Co-I; R01AG22018, Co-I; R01AG33678, Co-I; R01AG36836, Co-I; R01AG41797, Co-I; R01AG42210, Co-I; U01AG46152, MPI; and Illinois Department Public Health

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Rush Alzheimer's Disease Center (R.S.W., A.W.C., P.A.B., G.M.H., L.P.H., R.C.S., S.N., J.A.S., D.A.B.) and Departments of Behavioral Sciences (R.S.W., P.A.B.), Neurological Sciences (R.S.W., A.W.C., J.A.S., D.A.B.), Pathology (S.N., J.A.S.), and Family Medicine (R.C.S.), Rush University Medical Center, Chicago, IL; and Departments of Psychiatry and Neurology (S.E.A.), University of Pennsylvania, Philadelphia.
  1. Correspondence to Dr. Wilson: rwilson{at}rush.edu
View Full Text

Article usage

Article usage: July 2014 to January 2023

AbstractFullPdfSource
Jul 20142423024Highwire
Aug 2014465129135Highwire
Sep 2014725203136Highwire
Oct 20145601726Highwire
Nov 2014335812Highwire
Dec 201422418669Highwire
Jan 20154323224Highwire
Feb 2015193915Highwire
Mar 201525466Highwire
Apr 2015187912Highwire
May 2015252104Highwire
Jun 201517736Highwire
Jul 201515635Highwire
Aug 201516343Highwire
Aug 2015075pmc
Sep 201515421Highwire
Sep 201502810pmc
Oct 201516101Highwire
Oct 201502215pmc
Nov 201511904Highwire
Nov 201502213pmc
Dec 201513900Highwire
Dec 201501711pmc
Jan 201614511Highwire
Jan 201601613pmc
Feb 20168900Highwire
Feb 20160116pmc
Mar 20168620Highwire
Mar 20160229pmc
Apr 20168803Highwire
Apr 201602816pmc
May 201614711Highwire
May 201601810pmc
Jun 201610012Highwire
Jun 201601112pmc
Jul 20168903Highwire
Jul 2016075pmc
Aug 20169504Highwire
Aug 2016085pmc
Sep 20169230Highwire
Sep 20160146pmc
Oct 201615933Highwire
Oct 201602014pmc
Nov 201611811Highwire
Nov 2016074pmc
Dec 201612422Highwire
Dec 20160123pmc
Jan 201710313Highwire
Jan 20170148pmc
Feb 20179112Highwire
Feb 2017087pmc
Mar 20178202Highwire
Mar 20170133pmc
Apr 20177511Highwire
Apr 201771312pmc
May 20178613Highwire
May 201781617pmc
Jun 20177522Highwire
Jun 201741415pmc
Jul 20178411Highwire
Jul 2017101516pmc
Aug 20176300Highwire
Aug 201761716pmc
Sep 20176200Highwire
Sep 201781617pmc
Oct 20177100Highwire
Oct 201761620pmc
Nov 20177511Highwire
Nov 2017142333pmc
Dec 20175711Highwire
Jan 20185401Highwire
Feb 201813220Highwire
Mar 20188511Highwire
Apr 201811700Highwire
Apr 201871210pmc
May 201811611Highwire
Jun 20188600Highwire
Jun 201851112pmc
Jul 201810201Highwire
Aug 20184311Highwire
Aug 20184910pmc
Sep 20186221Highwire
Oct 20187015Highwire
Nov 201810122Highwire
Dec 20187100Highwire
Jan 20196711Highwire
Feb 20195710Highwire
Mar 20194471Highwire
Apr 20199320Highwire
May 20196222Highwire
Jun 20194534Highwire
Jul 20194001Highwire
Aug 20195701Highwire
Sep 20194643Highwire
Oct 20197121Highwire
Nov 20198733Highwire
Dec 20194023Highwire
Jan 20204200Highwire
Feb 20207113Highwire
Mar 20203610Highwire
Apr 20202800Highwire
May 20203000Highwire
Jun 20203602Highwire
Jul 20204511Highwire
Aug 20205521Highwire
Sep 20205611Highwire
Oct 20207521Highwire
Nov 20208010Highwire
Dec 20206910Highwire
Jan 20214300Highwire
Feb 20216410Highwire
Mar 20217200Highwire
Apr 20216320Highwire
May 20218600Highwire
Jun 20216320Highwire
Jul 20215710Highwire
Aug 202110610Highwire
Sep 20217410Highwire
Oct 20216310Highwire
Nov 20219010Highwire
Dec 20218200Highwire
Jan 20226200Highwire
Feb 20228210Highwire
Mar 20226810Highwire
Apr 20227851Highwire
May 20226810Highwire
Jun 20225913Highwire
Jul 20228901Highwire
Aug 202211022Highwire
Sep 20228710Highwire
Oct 202210851Highwire
Nov 20227300Highwire
Dec 20227061Highwire
Jan 20237011Highwire

Cited By...

Letters: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me